Indian pharmaceutical companies will be able to retain their dominant market share in the U.S. in selling generic drugs even ...

Welcome to the Cipla Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock. Stay ...

The freeze has put orders and forecasts, particularly those made months in advance, on hold. Read more at straitstimes.com.

The Nifty 50 closed below the 22,800 mark for the first time since June 5, 2024, settling at 22,796, down 117 points. The ...

The U.S. foreign aid freeze has severely impacted the supply chain for medical products in poor countries, causing potential shortages in HIV and malaria treatments. This disruption affects major ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

In fiscal 2024, the exports to the U.S. were worth $8.7 billion, or about 31% of total pharma exports, per data from government-backed trade body Pharmexcil. Trump's threat to raise tariffs sent ...

U.S. President Donald Trump's proposed tariffs on semiconductors and pharmaceutical imports threaten India's generics industry, a major supplier to the U.S. market. With 31% of their exports sent to ...

Equity benchmarks fall for fourth straight session on US tariff concerns, FPI selling, auto and pharma stock drag.

Cipla – The company earned 30% of its revenue from North America, ranking among the top 15 U.S. prescription drug providers with a focus on respiratory and oncology generics. Biocon – The U.S. was its ...

Indian benchmark indices ended in the red on Friday, extending their losing streak to a third consecutive week. The decline ...